About Alamar Biosciences
Alamar Biosciences is a company based in Fremont (United States) founded in 2018 by Steve Chen and Yuling Luo.. Alamar Biosciences has raised $230 million across 4 funding rounds from investors including HHS, Qiming Venture Partners and Sands Capital. Alamar Biosciences offers products and services including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology. Alamar Biosciences operates in a competitive market with competitors including Sequenta, Glympse Bio, Crescendo Bioscience, Harmonic Discovery and Seahorse Bioscience, among others.
- Headquarter Fremont, United States
- Founders Steve Chen, Yuling Luo
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alamar Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$230 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series C
Jan 12, 2026
-
Investors
HHS
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alamar Biosciences
Alamar Biosciences offers a comprehensive portfolio of products and services, including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables sensitive detection of protein biomarkers in fluid samples.
Automates proteomics analysis for efficient biomarker research.
Facilitates profiling of immunological protein biomarkers accurately.
Supports detection of neurological biomarkers for disease studies.
Aids in analyzing oncological protein biomarkers for research.
Unlock access to complete
Funding Insights of Alamar Biosciences
Alamar Biosciences has successfully raised a total of $230M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $50.0M
-
First Round
First Round
(01 Jul 2020)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series C - Alamar Biosciences | Valuation |
investors |
|
| Feb, 2024 | Amount | Series C - Alamar Biosciences | Valuation | Sands Capital |
|
| Sep, 2021 | Amount | Series B - Alamar Biosciences | Valuation | Sherpa Healthcare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alamar Biosciences
Alamar Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Qiming Venture Partners and Sands Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alamar Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alamar Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alamar Biosciences Comparisons
Competitors of Alamar Biosciences
Alamar Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequenta, Glympse Bio, Crescendo Bioscience, Harmonic Discovery and Seahorse Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| domain | founded_year | HQ Location |
Multiple human diseases are monitored noninvasively through urine-based analysis.
|
|
| domain | founded_year | HQ Location |
Molecular tests for autoimmune and inflammatory diseases are provided.
|
|
| domain | founded_year | HQ Location |
Developer of kinase inhibitor drugs for oncology
|
|
| domain | founded_year | HQ Location |
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alamar Biosciences
Frequently Asked Questions about Alamar Biosciences
When was Alamar Biosciences founded?
Alamar Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Alamar Biosciences located?
Alamar Biosciences is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Who is the current CEO of Alamar Biosciences?
Yuling Luo is the current CEO of Alamar Biosciences. They have also founded this company.
Is Alamar Biosciences a funded company?
Alamar Biosciences is a funded company, having raised a total of $230M across 4 funding rounds to date. The company's 1st funding round was a Series B of $80M, raised on Jul 01, 2020.
What does Alamar Biosciences do?
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The companys proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Who are the top competitors of Alamar Biosciences?
Alamar Biosciences's top competitors include Sequenta, Glympse Bio and Harmonic Discovery.
What products or services does Alamar Biosciences offer?
Alamar Biosciences offers NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology.
Who are Alamar Biosciences's investors?
Alamar Biosciences has 9 investors. Key investors include HHS, Qiming Venture Partners, Sands Capital, Sherpa Healthcare Partners, and Morningside.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.